{"schema_version":"secwatch.filing_event.v1","accession":"0001367644-24-000093","form_type":"8-K","ticker":"EBS","cik":"0001367644","company_name":"Emergent BioSolutions Inc.","filed_at":"2024-05-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.108459+00:00","generated_at":"2026-06-01T07:38:12.989919+00:00","sec_items":["5.02","5.07","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Emergent BioSolutions approves 2.1M share increase to stock plan; reports NARCAN OTC launch, DoD contracts","bullets":["Stockholders approved 2.1M share increase to stock incentive plan; full-value awards now count one-for-one.","Elected directors DeGolyer, Fowler, White; say-on-pay passed; EY ratified as auditor.","Launched OTC NARCAN Nasal Spray; FDA approved two-dose anthrax vaccine CYFENDUS.","Won $379.6M DoD contract for RSDL kits and $235.8M contract for BioThrax.","Cut ~$240M annualized OpEx; extended secured credit facility to May 2025; divested Travel Health up to $380M."],"urls":{"canonical":"https://secwatch.observer/filing/0001367644-24-000093","json":"https://secwatch.observer/filing/0001367644-24-000093.json","markdown":"https://secwatch.observer/filing/0001367644-24-000093.md","text":"https://secwatch.observer/filing/0001367644-24-000093.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1367644/000136764424000093/0001367644-24-000093-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1367644/000136764424000093/ebs-20240523.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T07:38:12.989919+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}